IMUC ImmunoCellular Therapeutics to Present at the 13th Annual BIO CEO & Investor Conference 8:00 am ET 02/11/2011- Business Wire LOS ANGELES--(BUSINESS WIRE)--Feb. 11, 2011-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that Manish Singh, Ph.D., the company's chief executive officer, will deliver a corporate overview at the upcoming 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh's presentation will take place on Monday, February 14, 2011 at 2:30 p.m. on the 4th Floor.
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma.. The Company's “off the shelf” therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011. To learn more about IMUC, please visit www.imuc.com.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.